Evidence map›Paper›PMID 35915202›Full record

ArticleJournal of gastrointestinal cancer2023

The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT.

Margherita Rimini, Pierfrancesco Franco, Federica Bertolini, De Bari Berardino, Zampino Maria Giulia, Vegge Stefano, Kalliopi Andrikou, Francesca Arcadipane, Martina Napolitano, Lavajo Vieira Buno and 6 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of gastrointestinal cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 4 countries.

Margherita RiminiOncologic Department, IRCCS San Raffaele Scientific Institute Hospital, 20019, Milan, Italy.ORCID http://orcid.org/0000-0002-4047-2585
Pierfrancesco FrancoDepartment of Oncology - Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy. pierfrancesco.franco@unito.it.
Federica BertoliniDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
De Bari BerardinoRadiation Oncology, Centre Hospitalier Universitaire de Besançon, 25000, Besançon cedex, France.
Zampino Maria GiuliaDivision of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Vegge StefanoRadiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Kalliopi AndrikouOncologic Department, Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori, IRCCS, Meldola (Forlì), Italy.
Francesca ArcadipaneDepartment of Oncology - Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy.
Martina NapolitanoDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Lavajo Vieira BunoRadiation Oncology, Centre Hospitalier Universitaire de Besançon, 25000, Besançon cedex, France.
Gerardi Marianna AlessandraDivision of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Francesco OliveroDepartment of Oncology - Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy.
Filippo FerreriDepartment of Oncology - Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy.
Umberto RicardiDepartment of Oncology - Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy.
Stefano CascinuOncologic Department, IRCCS San Raffaele Scientific Institute Hospital, 20019, Milan, Italy.
Andrea Casadei-GardiniOncologic Department, IRCCS San Raffaele Scientific Institute Hospital, 20019, Milan, Italy.
Department of Medical Sciences · BYVita-Salute San Raffaele University · ITCentre Hospitalier Universitaire de Besançon · FREuropean Institute of Oncology · ITUniversity of Modena and Reggio Emilia · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale Policlinico San Martino · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimAnal squamous cell carcinoma (SCC) and oropharyngeal cancer (OPC) are rare tumors associated with HPV infection. Bioumoral predictors of response to chemoradiation (CT-RT) are lacking in these settings. With the aim to find new biomarkers, we investigated the role of eosinophils in both HPV-positive anal SCC and HPV-related oropharyngeal cancer (OPC).

methodsWe retrieved clinical and laboratory data of patients with HPV-positive anal SCC treated with CT-RT in 5 institutions, and patients with locally advanced OPC SCC treated with CT-RT in 2 institutions. We examined the association between baseline eosinophil count (the best cutoff has been evaluated by ROC curve analysis: 100 × 10^9/L) and disease-free survival (DFS). Unadjusted and adjusted hazard ratios by baseline characteristics were calculated using the Cox proportional hazards model.

resultsThree hundred four patients with HPV-positive anal SCCs and 168 patients with OPCs (122 HPV-positive, 46 HPV-negative diseases) were analyzed. In anal SCC, low eosinophil count (< 100 × 10^9/L) correlates to a better DFS (HR = 0.59; p = 0.0392); likewise, in HPV-positive OPC, low eosinophil count correlates to a better DFS (HR = 0.50; p = 0.0428). In HPV-negative OPC, low eosinophil count confers worse DFS compared to high eosinophil count (HR = 3.53; p = 0.0098). After adjustment for age and sex, eosinophils were confirmed to be independent prognostic factors for DFS (HR = 4.55; p = 0.0139).

conclusionEosinophil count could be used as a prognostic factor in anal HPV-positive SCC. The worse prognosis showed in HPV-positive patients with high eosinophil count is likely to derive from an unfavorable interaction between the HPV-induced immunomodulation and eosinophils, which may hamper the curative effect of RT.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellOropharyngeal NeoplasmsPapillomavirus InfectionsEosinophilsHumansPrognosisRetrospective StudiesTomography, X-Ray ComputedChemoradiotherapyEosinophilsHPVOropharyngeal cancerPrognostic factorSquamous cell anal cancer

Identifiers

PMID35915202
PMCPMC9342937
OpenAlexW4289343296

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.